Circulating tumor markers: Predictors of incomplete cytoreduction and powerful determinants of outcome in pseudomyxoma peritonei

被引:27
|
作者
Kusamura, Shigeki [1 ]
Hutanu, Ionut [2 ]
Baratti, Dario [1 ]
Deraco, Marcello [1 ]
机构
[1] Fdn IRCCS Ist Nazl Tumouri Milano, Dept Surg, Peritoneal Surface Malignancy Program, I-20133 Milan, Italy
[2] Univ Med & Pharm Gr T Popa, Iasi, Romania
关键词
cytoreductive surgery; hyperthermic intraperitoneal chemotherapy; pseudomyxoma peritonei; circulating Tumor markers; prognosis; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; APPENDICEAL ORIGIN; CARCINOEMBRYONIC ANTIGEN; SURFACE MALIGNANCY; CARCINOMATOSIS; SURGERY; CAPECITABINE; PERFORMANCE; MORBIDITY; TOXICITY;
D O I
10.1002/jso.23329
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Incomplete cytoreduction (IC) is one of the main prognostic factor in pseudomyxoma peritonei (PMP). We evaluated the ability of preoperative Ca125, CEA, and Ca19-9 to predict IC and prognosis in PMP. Methods One hundred fifty-six cases elected candidate to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy from 1996 to 2011 were included in the study. We assessed the: (1) optimal cut-off values for circulating Tumor markers (CTM) in predicting IC (residual disease >2.5mm) using receiver-operating characteristics (ROC); (2) discriminant power of CTM and risk prediction models for IC by calculating the area under ROC curve (AUC-ROC); (3) prognostic factors using Cox proportional-hazard model. Results Optimal cut-offs were 125U/ml for Ca125, 18ng/ml for CEA, and 89U/ml for Ca19-9. The AUCs-ROC were 0.76, 0.68, and 0.69 for Ca125, CEA, and Ca19-9, respectively. The addition of CTM to risk prediction model that considered preoperative clinicopathological factors increased marginally the AUC-ROC (0.80-0.84). Ca125>125U/ml, Ca19-9>89U/ml independently affected overall survival. Conclusions Preoperative CTMs were reasonable but not perfect discriminators of IC. Moreover, Ca125 and Ca19-9, using new cut-off values, were proven to be new strong prognostic factors that overcome the value of disease extension and histological subtype. J. Surg. Oncol. 2013;108:1-8. (c) 2013 Wiley Periodicals, Inc.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 17 条
  • [1] Prognostic Impact of Pathology, Cytoreduction, and Tumor Markers in Pseudomyxoma Peritonei
    Lopes, Andre
    de Mello, Evandro Sobroza
    Mendoza Lopez, Rossana Veronica
    Leonardi, Paulo Cesar
    Ribeiro Jr, Ulysses
    JOURNAL OF SURGICAL RESEARCH, 2022, 274 : 68 - 76
  • [2] Nomogram to Predict Incomplete Cytoreduction for Pseudomyxoma Peritonei
    Bai, Mingjian
    Wang, Shilong
    Liang, Guowei
    Cai, Ying
    Lu, Yiyan
    Hou, Nianzong
    Ma, Ruiqing
    Xu, Hongbin
    Zhang, Man
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (02) : 885 - 892
  • [3] The role of baseline inflammatory-based scores and serum tumor markers to risk stratify pseudomyxoma peritonei patients treated with cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
    Kusamura, S.
    Baratti, D.
    Hutanu, I.
    Gavazzi, C.
    Morelli, D.
    Iusco, D. R.
    Grassi, A.
    Bonomi, S.
    Virzi, S.
    Haeusler, E.
    Deraco, M.
    EJSO, 2015, 41 (08): : 1097 - 1105
  • [4] Prognostic Factors in Pseudomyxoma Peritonei with Emphasis on the Predictive Role of Peritoneal Cancer Index and Tumor Markers
    Blaj, Sebastian
    Dora, David
    Lohinai, Zoltan
    Herold, Zoltan
    Szasz, Attila Marcell
    Herzberg, Jonas
    Kodacsi, Roland
    Baransi, Saher
    Schlitt, Hans Juergen
    Hornung, Matthias
    Werner, Jens M.
    Slowik, Przemyslaw
    Acs, Miklos
    Piso, Pompiliu
    CANCERS, 2023, 15 (04)
  • [5] Serum and ascites tumor markers in the diagnostic and prognostic prediction for appendiceal pseudomyxoma peritonei
    Wang, Bing
    Ma, Ruiqing
    Rao, Benqiang
    Xu, Hongbin
    BMC CANCER, 2023, 23 (01)
  • [6] ASO Author Reflections: Incomplete Cytoreduction Prediction Model for Pseudomyxoma Peritonei
    Bai, Mingjian
    Xu, Hongbin
    Zhang, Man
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (SUPPL 3) : 574 - 574
  • [7] Hyperthermic intraperitoneal chemotherapy in patients with incomplete cytoreduction for appendiceal pseudomyxoma peritonei: a 10-year treatment experience in China
    Wang, Bing
    Ma, Ruiqing
    Shi, Guanjun
    Fan, Xiwen
    Rao, Benqiang
    Xu, Hongbin
    ORPHANET JOURNAL OF RARE DISEASES, 2024, 19 (01)
  • [8] Prognostic Value of Circulating Tumor Markers in Patients with Pseudomyxoma Peritonei Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    Dario Baratti
    Shigeki Kusamura
    Antonia Martinetti
    Ettore Seregni
    Barbara Laterza
    Daniela G. Oliva
    Marcello Deraco
    Annals of Surgical Oncology, 2007, 14 : 2300 - 2308
  • [9] Prognostic value of circulating tumor markers in patients with Pseudomyxoma Peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Baratti, Dario
    Kusamura, Shigeki
    Martinetti, Antonia
    Seregni, Ettore
    Laterza, Barbara
    Oliva, Daniela G.
    Deraco, Marcello
    ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (08) : 2300 - 2308
  • [10] Complete Cytoreduction for Pseudomyxoma Peritonei Is Optimal but Maximal Tumor Debulking May Be Beneficial in Patients in Whom Complete Tumor Removal Cannot Be Achieved
    Dayal, Sanjeev
    Taflampas, Panagiotis
    Riss, Stefan
    Chandrakumaran, Kandiah
    Cecil, Thomas D.
    Mohamed, Faheez
    Moran, Brendan J.
    DISEASES OF THE COLON & RECTUM, 2013, 56 (12) : 1366 - 1372